Drugs / XP20B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00655291 | Apr → Aug 2008 | — | Xanodyne Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XP20B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00655291 ↗ |